• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Jonathan Hirsch: Precision Medicine Is the Future of Value-Based Cancer Care

Video

Precision medicine has demonstrated clinical utility and cost-effectiveness, which is why many believe this approach will be key to value-based cancer care in the future, said Jonathan Hirsch, founder and president of Syapse.

Precision medicine has demonstrated clinical utility and cost-effectiveness, which is why many believe this approach will be key to value-based cancer care in the future, said Jonathan Hirsch, founder and president of Syapse.

Transcript (slightly modified)

How can physicians use precision medicine to improve outcomes and reduce cost?

Precision medicine, we think, is one of the key elements to helping us all achieve the vision of value-based care. And the reason that I say that is because in a value-based paradigm you prize improved outcomes and you prize cost savings rather than revenue enhancing, and precision medicine is a key way to achieve that.

So we have partnered with Intermountain Healthcare over the past few years on precision oncology initiatives, and this culminated in a study that Intermountain published earlier this year in JOP [Journal of Oncology Practice], which demonstrated an improval in progression-free survival, approximately a doubling in PFS, and a net neutral impact on total cost of care when moving stage IV patients from a standard of care-based approach to a precision medicine approach. Specifically, to genomic profiling of their tumor and targeted therapeutic options, mostly commercially available drugs used on- and off-label.

This approach was dramatic for a health system to demonstrate the clinical utility as well as the cost effectiveness. So we really think that precision medicine is the future of cancer care, and we look forward to democratizing access for many health systems.

Related Videos
Ronesh Sinha, MD
Beau Raymond, MD
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Yuqian Liu, PharmD
Jenny Craven, PharmaD, BCPS
Kimberly Westrich, MA
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Sarah Bajorek, PhD, BCACP, MBA.
Pat Van Burkleo
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.